15 results about "Infected patient" patented technology

The application discloses a gel preparation preparation method for improving cervical HPV infection and establishing a preventive barrier, relates to the technical field of gel preparation, and aims to solve the technical problems that the existing treatment methods are mostly focused on treating infected patients, and there are obvious deficiencies in the prevention of HPV infection, especially in establishing an effective preventive barrier in uninfected people, including: a crushing mechanism, which is mainly used for crushing raw materials, the crushing mechanism comprises a cabinet body, a cabinet door is arranged on one side of the cabinet body, a crushing barrel is arranged in the cabinet door, and a rotating motor matched with the crushing barrel is arranged on the cabinet door; a reverse osmosis mechanism, which is mainly used for controlling the osmotic pressure of the gel. The application has the advantages of activating local immune cells of the cervix, promoting cytokine secretion, enhancing the immune clearance ability of the body to HPV virus, providing long-acting preventive protection for the cervix, and reducing the risk of HPV infection.

Disclosed is a drug vaporization and inhalation device. The present invention is configured such that when an infected patient with asthma, a coronavirus, or the like inhales a particulate drug, the drug is contained in vaporized steam, and therefore, the drug can sufficiently arrive at the lungs of the infected patient with asthma, a coronavirus, or the like, without loss, thereby preventing a given amount of the drug from remaining in an inhalation container and improving the drug inhalation efficiency of the infected patient with asthma, a coronavirus, or the like along with prevention of excessive inhalation of the drug.

The invention discloses a preparation method of a gel preparation for improving cervical HPV infection and establishing a prevention barrier, relates to the technical field of preparation of gel preparations, and aims to solve the problems that most of existing treatment methods focus on treatment of infected patients, and the existing treatment methods have a poor treatment effect on prevention of HPV infection, especially establishment of an effective prevention barrier in uninfected people. The raw material crushing device comprises a crushing mechanism which is mainly used for crushing raw materials, the crushing mechanism comprises a cabinet body, a cabinet door is arranged on one side of the cabinet body, a crushing barrel is arranged in the cabinet door, and a rotating motor matched with the crushing barrel to work is arranged on the cabinet door; and the reverse osmosis mechanism is mainly used for controlling the gel osmotic pressure. The invention has the advantages of activating local immune cells of the cervix uteri, promoting the secretion of cell factors, enhancing the immune clearance ability of the body to the HPV virus, providing long-acting prevention and protection for the cervix uteri, and reducing the HPV infection risk.

The invention belongs to the technical field of in-vitro molecular detection of pathogenic microorganisms, and particularly relates to a primer probe combination, a kit and a detection system for detecting entamoeba histolytica, giardia lamblia and cryptosporidium and application of the primer probe combination, the kit and the detection system. The primer and probe combination is obtained by optimizing primer and probe design and comprises primers and probes for detecting entamoeba histolytica, giardia blue and cryptosporidium, three types of parasite pathogens can be identified and detected on suspected infected patients at a time, the flux is high, the detection time is short, the detection time is short, and the detection efficiency is high. And the kit has the advantages of strong specificity, high sensitivity, good stability, short reaction time and the like. Furthermore, the kit containing the primer and probe combination is formed by optimizing a reaction system, a single tube in the kit can contain all primers, probes and components required by PCR reaction in a fully premixed form, the reaction system does not need to be prepared, the operation is simple, and the consumed time is short.

The invention relates to the technical field of medical detection, and provides Cas12a-crRNA for detecting gardnerella vaginalis, and the base sequence of the Cas12a-crRNA is as shown in SEQ ID NO. 1. The invention also provides an application of the Cas12a-crRNA in the construction of a Gardnerella vaginalis detection system. In addition, the invention also provides a CRISPR (clustered regularly interspaced short palindromic repeats)-Cas system, a method for rapidly detecting gardnerella vaginalis based on CRISPR, and application of the CRISPR-Cas system in preparation of a gardnerella vaginalis detection kit. The kit has the advantages that based on the CRISPR technology, the kit can be used for rapid early detection of BV infected patient specimens caused by excessive breeding of suspected gardnerella vaginalis, and the kit is low in detection cost and simple in process and has important significance on clinical diagnosis.

The invention discloses freeze-dried powder and capsules for treating intractable helicobacter pylori infection as well as a preparation method and application of the freeze-dried powder and capsules, and belongs to the technical field of biological medicines. The invention provides a preparation method of freeze-dried powder for treating intractable helicobacter pylori infection, which comprises the following steps: acquiring gastric mucous layer flushing fluid which contains gastric microorganisms; filling the obtained gastric mucous layer flushing fluid into an eggplant-shaped bottle, connecting a low-temperature rotator, and rotating for a certain time under a low-temperature condition until the bacterial liquid adheres to the wall; and after the bacterial liquid adheres to the wall, taking down the eggplant-shaped bottle, mounting the eggplant-shaped bottle on a freeze-drying machine, and freeze-drying at low temperature for a certain time to prepare freeze-dried powder. The capsule prepared from the freeze-dried powder prepared by using the preparation method disclosed by the invention can overcome gastrointestinal flora disorder caused by conventional anti-helicobacter pylori infection treatment, repair unbalanced gastric microbiota of an infected patient, and avoid complex operations or invasive operations possibly involved in traditional flora transplantation, such as gastroscopy or nasogastric tubes and the like.

The invention relates to a pyridone derivative as shown in a formula (I) or a stereoisomer thereof, a prodrug of the pyridone derivative, a pharmaceutically acceptable salt, a pharmaceutical composition containing the formula (I), and application of the pyridone derivative or the stereoisomer thereof, the prodrug of the pyridone derivative, the pharmaceutically acceptable salt and the pharmaceutical composition in preparation of a medicine for preventing and / or treating HIV (Human Immunodeficiency Virus) infection. The compound disclosed by the invention has remarkable anti-HIV virus activity, relatively low solubility and very low clearance rate, is suitable for developing a long-acting injection prevention and treatment scheme, and is used for preparing a medicine of an HIV virus integrase inhibitor or a medicine composition containing the medicine so as to benefit patients infected by HIV viruses.

The application discloses a protein polypeptide for marker use in clinical diagnosis of non-tuberculous mycobacterial infection, comprising an amino acid sequence as shown in SEQ NO.1 or an amino acid sequence as shown in SEQ NO.2. The application also discloses proteins and uses thereof. The protein polypeptide of the application can specifically stimulate lymphocytes of a mycobacterium abscessus infected patient to secrete cytokines such as IFN-gamma, and therefore, the protein polypeptide can be used for marker use in clinical diagnosis of the mycobacterium abscessus infected patient.

Compounds, compositions, and methods of treatment and prevention of HIV infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV in an infected patient.

This invention discloses a biomarker for evaluating the immune status of COVID-19 vaccines and its application. The biomarker includes any one or a combination of at least two of the following SARS-CoV-2 viral peptides: M1, N16, N24, S15, S39, S44, S64, S82, S95, S104, or S115. This invention accurately identifies differences in peptide-specific antibody responses between asymptomatic and symptomatic patients. Through clustering heatmaps, it determines the differences in responses to peptides such as M1, N24, S15, S64, S82, S104, and S115 between vaccinated individuals and infected individuals. This effectively distinguishes between infected patients and vaccinated individuals, as well as between asymptomatic and symptomatic patients, providing a reference for COVID-19 treatment and peptide vaccine development.

The invention discloses a joint detection marker for diagnosis and differential diagnosis of rhinomyelitis and application of the joint detection marker. The marker comprises cell factor E-selectin protein / nucleic acid in a blood sample of an infected patient and an antibody aiming at rhinomyelitis HCP1 protein. The invention creatively provides the combined marker for diagnosing the infection of the rhinotrichum-like disease, and the combined marker can be used for differential diagnosis of the current symptom and the previous infection of the rhinotrichum-like disease. The combined marker also has the potential of being used as a target spot for preventing and treating burkholderia pseudomallei infection.

The invention provides an antibody combined with HPV66 L1 protein or an antigen binding fragment thereof and a pharmaceutical composition containing the antibody, and further provides a polynucleotide molecule for coding the antibody or the antigen binding fragment thereof, and an expression vector for expressing the antibody or the antigen binding fragment thereof. The antibody or the antigen binding fragment thereof can be widely applied to infection detection of the HPV66 virus in a clinical sample, can be prepared into vaginal gel, vaginal cleaning liquid, external washing liquid, vaginal suppository, freeze-dried powder, vaginal effervescent tablets and the like, is used for prevention and / or treatment of HPV66 infected patients, and can effectively improve the clinical negative conversion rate of the HPV66 patients. The invention has important significance on female reproductive health and public health prevention and control.

Coronavirus disease of 2019 (COVID-19) is an acute viral infection that can trigger complicated immune system responses depending on the host. This disclosure discloses immunotherapy methods combining immunomodulators and antivirals to prevent and to reduce the severity of a COVID-19 infection. Successful treatment of COVID-19 requires prevention, early recognition and detection, the ruling out of co-infections, serial laboratory monitoring, and clinical monitoring for worsening and timely treatments during the acute phase and post-viral syndrome. Using this disclosure as preventive, management and therapeutic options for COVID-19, infected patients can be more resilient to viral challenges, recovering faster with less organ damages and adverse residual effects.

The present inventors have identified an miRNA capable of greatly modulating the inflammatory response induced by Clostridium difficile. They thus propose incorporating this miRNA into a pharmaceutical composition for preventing or reducing the harmful effects of this infection on the bowels of infected patients. This microRNA is miR-27a-5p. Advantageously, this miRNA can be linked to a matrix, incorporated into particles, or conveyed by a vector. It can be administered to infected subjects for therapeutic purposes.

The invention belongs to the technical field of biological medicine, and particularly relates to application of polypeptide in distinguishing infection of novel coronavirus (SARS-CoV-2) with different severity degrees, and the polypeptide is KTFPPTEPKKDKKKK (SEQ ID NO: 1) and / or ALPQRQKKQQTVTLL (SEQ ID NO: 2). By detecting the abundance of the IgA antibody combined with the polypeptide, the severity of the SARS-CoV-2 infected patient can be effectively distinguished.